Impact of lapatinib plus trastuzumab versus single-agent lapatinib on quality of life of patients with trastuzumab-refractory HER2+ metastatic breast cancer
2011 · Annals of Oncology · 31 citations
https://doi.org/10.1093/annonc/mdr014
J
J. O’Shaughnessy
Claim or correct this author profile
Claim this profile or suggest corrections to the name, affiliation, bio, photo, or paper titles. Approved changes appear as verified CitedEvidence overlays.
69
Papers
1.8K
Citations
14
h-index
17
i10-index
J. O’Shaughnessy is an academic researcher from Sarah Cannon Research Institute. The author has contributed to research in topics: Cancer Treatment and Pharmacology & Advanced Breast Cancer Therapies & HER2/EGFR in Cancer Research. The author has an h-index of 14, co-authored 59 publications.
Papers by this author
works297O Imlunestrant (Imlu) with or without abemaciclib (Abema) in advanced breast cancer (ABC): A subgroup analysis in CDK4/6 inhibitor (CDK4/6i)-pretreated patients (pts) from EMBER-3
2025 · ESMO Open · 2 citations
https://doi.org/10.1016/j.esmoop.2025.104869
P009: Adjuvant Abemaciclib Plus Endocrine Therapy for HR+, HER2-, High-risk Early Breast cancer: Results From a Preplanned monarchE Overall Survival Interim Analysis, Including 5-year Efficacy Outcomes
2025 · The Breast · 0 citations
https://doi.org/10.1016/j.breast.2025.103903
463eTiP HERTHENA-breast03: A phase 2, randomized, open-label study evaluating neoadjuvant patritumab deruxtecan + pembrolizumab before or after pembrolizumab + chemotherapy for early-stage TNBC or HR-low+/HER2− breast cancer
2025 · Annals of Oncology · 0 citations
https://doi.org/10.1016/j.annonc.2025.08.886
Research topics
topicsChat about Author
Papers
Chat
Click to start Chat